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Background: John Cunningham Virus (JCV) was involved in pre-malignant lessions and carcinogenesis of the colon. The 
purpose of this study was to detect and analyze JCV T-Ag expression in mild and severe dysplasia adenomatous polyp as 
well as low and high grade adenocarcinoma of the colon.
Materials and Methods: This study used analytic descriptive, cross sectional approach. The samples’ paraffin blocks were 
taken from colon adenomatous polyp cases (all grades of dysplasia) and cases of  colon adenocarcinoma (all degrees) at 
Anatomical Pathology Laboratory, School of Medicine, Atma Jaya Catholic University of Indonesia from 2010-2014 (5 years 
period).  Samples  were  reviewed  from  HE  slides  to  determine  histopathologic  diagnosis,  grades  of  dysplasia  and 
grading.  We  performed  immunohistochemistry  staining  with  monoclonal  antibody  anti–SV  40-T-Ag  to  detect  JCV 
T-Ag  expression.
Results: We found 7 cases of colon adenomatous polyp, of which 4 (57%) were mild dysplasia and 3 (43%) were severe 
dysplasia. Positive expression of JCV T-Ag was detected in 1 (14%) mild dysplasia case. Data analysis using Fischer’s Exact 
Test was p>0.05. We also found 16 cases of colon adenocarcinoma. 14 cases (87.5%) of low grade variant and 2 cases 
(12.5%) of high grade variant. Positive expression of JCV T-Ag was detected in 2 (12.5%) low grade cases. Data analysis using 
Fischer’s Exact Test was p>0.05. 
Conclusion: There was no difference of JCV T-Ag expression in colon adenomatous polyp (mild-severe dysplasia) and 
colon adenocarcinoma (low-high grade) cases at Anatomical Pathology Laboratory School of Medicine, Atma Jaya Catholic 
University of Indonesia 2010-2014.
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Introduction
Colon adenomatous polyp otherwise known as colonic 
adenomas, are commonly encountered benign neoplasms or 
premalignant lesions; it has a typical feature of glandular 
epithelial dysplasia.1 Colon adenomatous polyp may develop 
into a malignant neoplastic lesion, colon adenocarcinoma, 
which is the most common colorectal malignancy. 
Colorectal cancer occupies the 3rd and 4th place in the world 
for incidence and leading cause of death respectively. As for 
Indonesia, colorectal cancer is ranked 2nd after lung cancer 
in men and ranked 3rd after breast and cervical cancer in 
women.2 
 Polyps may be prominent in the colonic mucosa 
(stemmed or sessile) with dysplasia of epithelial or glandular 
cells. Dysplasia lesions in colon adenomatous polyps can 
be divided into 2 categories: which is mild dysplasia and 
severe dysplasia. Colon adenocarcinoma is a malignant 
neoplastic lesion originating from mucosal epithelial cells 
or colonic glands. It can also be divided into 2 categories 
according to the grading of dysplasia, which is low grade 
(good to moderate differentiation) or high grade (poor to 
undifferentiated).1   
 Risk factors for these conditions include genetics, age, 
lifestyle and autoimmune diseases such as inflammatory 
bowel disease (IBD). Another risk factor that has come to 
light is from infectious agents. Infectious agents such as 
John Cunningham virus (JCV) also play a role in the process 
of neoplasm to carcinogenesis in the colon.3 JCV can be 
found anywhere around the world and is an oncogenic virus 
belonging to the family of polyomaviridae virus. This family 
of virus has a characteristic circular shaped, double stranded 
DNA and is unenveloped.4 The JCV genome consists of 3 
parts, the early region, late region and noncoding region. 
Early region’s function is to encode nonstructural proteins 
such as T-Ag and t-Ag, while the late region serves to encode 
viral capsid proteins (VP1, VP2 and VP3). The noncoding 
region contains the origin of DNA replication and serves to 
regulate the early and late gene.5 The JCV is not the cause of 
colorectal neoplasms, but it is one of the relevant risk factor 
that can facilitate the progression and development of one or 
more tumors in humans6 such as brain tumors, esophageal 
cancer and also colorectal tumors. 
 Nearly 80% of the human population is susceptible 
to JCV infections and about 80% of adults have specific 
antibodies against JCV, as a sign of a history of being 
infected with the virus. JCV infections generally occurs 
during childhood as an asymptomatic and latent infection.7,8 
Transmission from human to human is not yet known, 
but JCV can be found in human waste residues indicating 
the possibility of fecal-oral transmission. In addition, 
JCV can infect through the respiratory pathway. This 
is confirmed by the discovery of JCV on tonsils which 
will then replicate in the  lymphoid  and  latent  cells  in 
the  kidneys . The  latent JCV will be reactivated if the 
immune system is weakened (i.e., in leukemia, lymphoma 
or  immunosuppressive  drug).7-9  The  activated  JCV  will 
take 2 different pathways depending on the infected cells 
(permissive or non-permissive cells). If permissive cell is 
infected, the cell will facilitate the virus’ DNA replication, 
then the viruses will be released through the lytic  pathway, 
and the resulting  disease is called Progressive Multifocal 
Leukoencephalopathy (PML). Whereas if non-permissive 
cells are infected, these cells won’t facilitate the virus’ DNA 
replication. The virus will then  enter  abortive  phase or will 
lead to oncogenesis.7,10 
 T-Ag protein is thought to play an important role 
in the occurrence of neoplasms of carcinogenesis such 
as transforming  premalignant  neoplastic  lesions  into 
colorectal cancer. This is presumed due to expression of 
T-Ag  would  result  in  inactivation  of  tumor  suppressor 
genes such as p53, pRb and APC/ β-catenin which play a 
role in DNA repair.11 The JCV T-Ag expression will bind, 
inactivate p533 and interfere with p21WAF-1 regulation. 
This leads to damaged DNA going forward to the next 
phase without any inhibition from p53 and p21, resulting in 
uncontrolled cell proliferation.12 Disrupted p21 regulation 
will cause pRB phosphorylation by cyclin-cdk  and release 
E2F. In addition, E2F free from pRb-E2F bond is also caused 
by the interaction of T-Ag and pRB. Free E2F will enter 
into the nucleus and cause cells to continue proliferating.13,14 
T-Ag will bind free β-catenin; increase the stability of 
β-catenin and accelerate induction of cell proliferation. The 
β-catenin mutation will also stimulate cell proliferation 
genes.15
 Several previous studies on the potential roles of JCV 
in the occurrence of colorectal cancer has been done, but 
there has been no such research in Indonesia. Some of these 
studies takes place in Japan10, Jordan7, China4 and Taiwan16. 
This is the basis of our interest to analyze and detect the 
presence of T-Ag protein from JCV on the tissue biopsy/
colectomy of colon adenomatous polyp cases as well as 
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the colon adenocarcinoma cases at the Anatomic Pathology 
Laboratory of the Faculty of Medicine, Unika Atma Jaya/
Atma Jaya Hospital Jakarta for the period of 5 years (2010-
2014).
Materials and methods
 This study used cross-sectional analysis design with 
consecutive sampling. Data were taken from medical 
record of all patients undergoing biopsy/colectomy and 
based on the histopathologic evidence, diagnosed with 
colon adenomatous polyp or colon adenocarcinoma in 
Anatomic Pathology Laboratory of Faculty of Medicine 
UNIKA Atma Jaya/Atma Jaya Hospital Jakarta for 5 year 
period (2010-2014). Review of paraffin blocks and slides 
were done to ensure availability and sample correctness as 
well as to evaluate diagnosis accuracy, grades of dysplasia 
and differentiation. Additional immunohistochemical 
examination were done to detect the presence JCV T-Ag 
expression using the anti-SV40 T-Ag monoclonal antibody. 
Result is positive if nucleus of tumour mass turn brownish. 
Data analysis is done using Fisher’s Exact Test on SPSS 19.
Immunohistochemical Assay
Immunohistochemical staining in this study is done as 
follows, paraffin blocks were sectioned, dewaxed with 
xylene (2 station, 5 minutes each), rehydrated with 
gradient alcohol (absolute, 96%, 80% and 70%), and then 
treated with hydrogen peroxide (blocking) for 5 minutes, 
rinse with water. Heated until 110oC for 15 minutes in 
decloaking chamber (Diva), left to cool. Washed with PBS 
for 3 minutes, blocking was resumed with sniper for 15 
minutes, then  primary  antibody  were  added,  left  to  sit 
for  30  minutes. Stained with universal link for 15 minutes, 
TrekAvidin-HRP for 15 minutes. Then, DAB + substrate 
buffer was used for 2-5 minutes. Washed with running water 
for 5 minutes, stained with hematoxylin for 1-2 minutes, 
then rinsed with running  water  again  for  5  minutes. 
Slides were dehydrated with gradient alcohol (70%, 80%, 
90%, absolute), clarified with xylene,  sealed with entellan 
and cover glass. Positive control used paraffin blocks of 
non-Hodgkin’s lymphoma, whereas negative controls used 
colon adenocarcinoma biopsy/colectomy tissue without 
antibody administration.
Results
In Table 1, from 7 samples of colon adenomatous polyp 
cases, 1 sample (14%) gave positive expression results 
on T-Ag JCV. The samples were from the mild dysplasia 
cases. Similarly, in Table 2, from 16 samples of colon 
adenocarcinoma cases, 2 samples (12.5%) gave positive 
expression results to T-Ag JCV. Both of the cases were from 
the low grade variety. Meanwhile the expression of of JCV 
T-Ag (+) and JCV T-Ag (-) in each groups are shown in 
Figure 1 and 2.
Colon Adenomatous Polyp JCV + JCV - n
Mild Dysplasia 1(14%) 3 (43%) 4 (57%)
Severe Dysplasia 0 (0%) 3 (43%) 3 (43%)
n 1 (14%) 6 (86%) 7 (100%)
Table 1. Frequency distribution and percentage of colon adenomatous polyp 
with mild and severe dysplasia to JCV T-Ag expression.
Table 2. Frequency distribution and percentage of low and high grade 
colon adenocarcinoma to JCV T-Ag expression.
Colon Adenocarcinoma JCV + JCV - n
Low Grade 2 (12.5%) 12 (75%) 14 (87.5%)
High Grade 0 (0%) 2 (12.5%) 2 (12.5%)
n 2 (12.5%) 14 (87.5%) 16 (100%)
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Discussion
This results suggests that JCV T-Ag can be found at 
different levels of dysplasia or differentiation, from pre-
cancerous lesions to colorectal malignancies. Statistical 
analysis reveals there is no significant difference in JCV 
T-Ag expression between mild degree dysplasia and severe 
degree dysplasia of colon adenomatous polyp. Similarly, 
there was no significant difference in JCV T-Ag expression 
between low and high grade colon adenocarcinoma. It is 
possible that JCV T-Ag expression is carried over from early 
stages such as mild dysplasia colon adenomatous polyp up 
until later stages such as high grade colon adenocarcinoma. 
This explains why JCV T-Ag expression can be found 
in varying degrees of dysplasia or differentiation and is 
carried on to more advanced stages. Similar results was 
also reported by Woon Tae Jung, et al.17 From 74 samples 
of colon adenomatous polyp cases, there were 12 samples 
A B
C D
Figure 1. A: Expression of JCV T-Ag (+) on positive control (non-Hodgkin’s lymphoma), 1000x magnification; B: Expression of JCV 
T-Ag (-) on negative control, 1000x magnification; C: Expression of JCV T-Ag (+) on colon adenoma polyp, 1000x magnification; 
D: Expression of JCV T-Ag (-) on colon adenomatous polyp, 400x magnification.
(16%) consisting of 1 case with severe dysplasia and 11 
mild dysplasia cases, which showed positive results for 
JCV T-Ag expression. This study also reported that there is 
no significant difference in JCV T-Ag expression between 
mild dysplasia and severe dysplasia. This study also states 
that JCV T-Ag is present in the early stage of colonic 
carcinogenesis. A similar study by Hori, et al., stated that 
of 21 colon adenomatous polyp cases there were 1 (4.8%) 
and from  23  cases of  colorectal  cancer, 6 (26.1%)  were 
JCV T-Ag positive.10 Lin, et al., also found that there is 
no significant association between the degree of colon 
adenocarcinoma differentiation and JCV T-Ag expression.16 
This explain that carcinogenesis in colon cancer is 
influenced by many other factors besides JCV, such as age, 
race, genetics and lifestyle. In addition, JCV subtype and 
epidemiologic differences will also influence the difference 
in expression results.18
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Figure 2. A: Expression of JCV T-Ag (+) on positive control (non-Hodgkin’s lymphoma), 1000x magnification; B: Expression of JCV 
T-Ag (-) on negative control, 1000x magnification; C: Expression of JCV T-Ag (+) on colon adenocarcinoma, 1000x magnification; 
D: Expression of JCV T-Ag (-) on colon adenocarcinoma, 1000x magnification. 
Conclusion
There was no difference in JCV T-Ag expression between 
mild and severe dysplasia in colon adenomatous polyp. 
There is also no significant difference between low and 
high grade colon adenocarcinoma regarding JCV T-Ag 
expression at the Anatomic Pathology Laboratory of Faculty 
of Medicine UNIKA Atma Jaya in 2010-2014.   
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